Program
HDM2020
A development code. Also written as “HDM2020 (FGFR2b-ADC)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Huadong Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 22 open or running | phase 1since Jul 18, 2025 | Jul 18, 2025 | Jan 31, 2027phase 1 · NCT07638891 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 18, 2025First study: phase 1 study in Solid TumorFirst studyNCT07098052 · 60 planned · China
- Jun 5, 2026Phase 1 study in Squamous Non-small Cell Lung Cancer(NSCLC)NCT07638891 · 150 planned · China
Ahead
- Jan 31, 2027Primary completion: phase 1 study in Squamous Non-small Cell Lung Cancer(NSCLC)NCT07638891
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07638891Squamous Non-small Cell Lung Cancer(NSCLC) · China | 1 | Recruiting | Jan 31, 2027 | 150 |
| NCT07098052Solid Tumor · China | 1 | Recruiting | Sep 30, 2026 | 60 |
How it is read
Names in the registry
- “HDM2020 (FGFR2b-ADC)”, 1 entry
- “HDM2020”, 1 entry
Codes read as this program: HDM2020.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.